secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001437749-23-020536
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Pharmaceuticals' auditor Armanino declines re-appointment; audit committee seeks new firm
--------------------------------------------------------------------------------

- Armanino LLP notified Reviva on July 18, 2023 it will not stand for re-appointment after Q3 2023 review.
- Reason: Armanino is transitioning away from providing audit services to public companies.
- Audit reports for FY2021 and FY2022 were unqualified; FY2022 included a going-concern paragraph.
- No disagreements or reportable events occurred during the period through July 18, 2023.
- Audit committee has begun search for a new independent registered public accountant for FY2023 audit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923020536/0001437749-23-020536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923020536/rvph20230721_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-020536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer